不同脑部疾病患者尿液AD7c-NTP阳性率分析

doi:10.3969/j.issn.1673-8640.2025.07.002

检验医学 ›› 2025, Vol. 40 ›› Issue (7): 642-647.DOI: 10.3969/j.issn.1673-8640.2025.07.002

不同脑部疾病患者尿液AD7c-NTP阳性率分析

吴钧¹, 陶月², 陈德柱³, 沙娇娇⁴, 杜靓佳⁵, 陈衣强⁶, 刘思远⁶, 宋宏岩², 郑茜⁷, 柏兵²()

1.南京医科大学附属脑科医院检验科，江苏南京 210024
2.南京大学医学院附属鼓楼医院检验科，江苏南京 210008
3.南京大学医学院附属鼓楼医院核医学科，江苏南京 210008
4.南京中医药大学鼓楼临床医学院检验科，江苏南京 210008
5.南京师范大学鼓楼临床医学院检验科，江苏南京 210008
6.南京大学医学院附属鼓楼医院精准医学中心，江苏南京 210008
7.南京大学医学院附属鼓楼医院健康管理中心，江苏南京 210008

收稿日期:2024-07-15 修回日期:2024-11-01 出版日期:2025-07-30 发布日期:2025-07-28
通讯作者: 柏兵，E-mail:bing.bai@nju.edu.cn。
作者简介:柏兵，E-mail:bing.bai@nju.edu.cn。
吴钧，男，1987年生，副主任技师，主要从事临床免疫学检验工作。
基金资助:
国家自然科学基金项目(82172354);国家自然科学基金项目(82472333);江苏省卫生健康委员会医学科研面上项目(M2021012);南京市卫生科技发展专项(ZKX22013);南京鼓楼医院临床研究专项资金资助项目(2022-LCYJ-MS-02);南京鼓楼医院医疗新技术项目(XJSFZLX202331)

Positive rate analysis of urinary AD7c-NTP of patients with different brain diseases

WU Jun¹, TAO Yue², CHEN Dezhu³, SHA Jiaojiao⁴, DU Liangjia⁵, CHEN Yiqiang⁶, LIU Siyuan⁶, SONG Hongyan², ZHENG Qian⁷, BAI Bing²()

1. Department of Clinical Laboratory ，the Brain Hospital Affiliated to Nanjing Medical University，Nanjing 210024，Jiangsu，China
2. Department of Clinical Laboratory，Nanjing Drum Tower Hospital，Nanjing University Medical School，Nanjing 210008，Jiangsu，China
3. Department of Nuclear Medicine，Nanjing Drum Tower Hospital，Nanjing University Medical School，Nanjing 210008，Jiangsu，China
4. Department of Clinical Laboratory，Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine，Nanjing 210008，Jiangsu，China
5. Department of Clinical Laboratory，Nanjing Drum Tower Hospital Clinical College of Nanjing Normal University，Nanjing 210008，Jiangsu，China
6. Center for Precision Medicine，Nanjing Drum Tower Hospital，Nanjing University Medical School，Nanjing 210008，Jiangsu，China
7. Health Management Center，Nanjing Drum Tower Hospital，Nanjing University Medical School，Nanjing 210008，Jiangsu，China

Received:2024-07-15 Revised:2024-11-01 Online:2025-07-30 Published:2025-07-28

摘要/Abstract

摘要：

目的探讨不同脑部疾病患者尿液阿尔茨海默病相关神经丝蛋白（AD7c-NTP）阳性率的分布情况，并分析其对阿尔茨海默病（AD）的诊断价值。方法收集2018年7月—2023年11月南京医科大学附属脑科医院10 208例患者的尿液AD7c-NTP酶联免疫吸附试验（ELISA）检测结果。根据临床诊断将所有患者分为37个组，比较各组尿液AD7c-NTP的阳性率。结果尿液AD7c-NTP总体阳性率为2.54%（259/10 208）。AD组、痴呆组、认知障碍组尿液AD7c-NTP阳性率分别为3.79%（19/501）、2.78%（5/180）和2.01%（6/298）。头昏/头痛/晕厥/眩晕组、抑郁障碍组尿液AD7c-NTP阳性率分别为0.81%（3/372）、1.91%（27/1 414），均显著低于AD组（χ²值分别为6.58、4.82，P<0.05）。面肌痉挛组尿液AD7c-NTP阳性率为20.00%（2/10），显著高于痴呆组、认知障碍组（P<0.05）。其他非痴呆类疾病各组尿液AD7c-NTP阳性率与AD组、痴呆组和认知障碍组比较差异均无统计学意义（P>0.05）。结论 AD、痴呆和认知障碍患者尿液AD7c-NTP阳性率较低，与其他大多数非痴呆类疾病患者AD7c-NTP阳性率无差异。尿液AD7c-NTP检测的临床价值有待进一步明确。

关键词: 阿尔茨海默病相关神经丝蛋白, 阿尔茨海默病, 痴呆

Abstract:

Objective To investigate the distribution of the positive rate of urinary Alzheimer's disease-associated neurofilament protein（AD7c-NTP）of patients with different brain diseases，and to analyze its diagnostic value for Alzheimer's disease（AD）. Methods The urinary AD7c-NTP enzyme-linked immunosorbent assay（ELISA）results of 10 208 patients in the Brain Hospital Affiliated to Nanjing Medical University from July 2018 to November 2023 were collected. All the patients were classified into 37 groups based on clinical diagnosis，and the positive rates of urinary AD7c-NTP in each group were compared. Results The overall positive rate of urinary AD7c-NTP was 2.54%（259/10 208）. The positive rates of urinary AD7c-NTP in AD group，dementia group and cognitive impairment group were 3.79%（19/501），2.78%（5/180）and 2.01%（6/298），respectively. The positive rates in the dizziness/headache/syncope/vertigo group（0.81%，3/372） and depressive disorder group（1.91%，27/1 414） were lower than those in AD group（χ²=6.58 and 4.82，respectively，P<0.05）. The hemifacial spasm group exhibited a higher positive rate（20.00%，2/10） compared to dementia and cognitive impairment groups（P<0.05）. No statistical significance in positive rates were observed between the remaining non-dementia disease groups and AD，dementia and cognitive impairment groups （P>0.05）. Conclusions The positive rate of urinary AD7c-NTP of patients with AD，dementia and cognitive impairment is relatively low，and there is no significant difference from the urinary AD7c-NTP positive rate of other non-dementia diseases. The clinical value of urinary AD7c-NTP determination remains to be further clarified.

Key words: Alzheimer's disease-associated neurofilament protein, Alzheimer's disease, Dementia

中图分类号:

R446.1

吴钧, 陶月, 陈德柱, 沙娇娇, 杜靓佳, 陈衣强, 刘思远, 宋宏岩, 郑茜, 柏兵. 不同脑部疾病患者尿液AD7c-NTP阳性率分析[J]. 检验医学, 2025, 40(7): 642-647.

WU Jun, TAO Yue, CHEN Dezhu, SHA Jiaojiao, DU Liangjia, CHEN Yiqiang, LIU Siyuan, SONG Hongyan, ZHENG Qian, BAI Bing. Positive rate analysis of urinary AD7c-NTP of patients with different brain diseases[J]. Laboratory Medicine, 2025, 40(7): 642-647.

图/表 2

参考文献 31

[1]	REN R, QI J, LIN S, et al. The China Alzheimer report 2022[J]. Gen Psychiatr, 2022, 35(1):e100751.
[2]	VAZ M, SILVESTRE S. Alzheimer's disease:recent treatment strategies[J]. Eur J Pharmacol, 2020,887:173554.
[3]	JACK C R Jr, BENNETT D A, BLENNOW K, et al. NIA-AA research framework:toward a biological definition of Alzheimer's disease[J]. Alzheimers Dement, 2018, 14(4):535-562.
[4]	JACK C R Jr, ANDREWS J S, BEACH T G, et al. Revised criteria for diagnosis and staging of Alzheimer's disease:Alzheimer's association workgroup[J]. Alzheimers Dement, 2024, 20(8):5143-5169.
[5]	KARIKARI T K, ASHTON N J, BRINKMALM G, et al. Blood phospho-tau in Alzheimer disease:analysis,interpretation,and clinical utility[J]. Nat Rev Neurol, 2022, 18(7):400-418.
[6]	GONZALEZ-ORTIZ F, KAC P R, BRUM W S, et al. Plasma phospho-tau in Alzheimer's disease:towards diagnostic and therapeutic trial applications[J]. Mol Neurodegener, 2023, 18(1):18.
[7]	PALMQVIST S, TIDEMAN P, CULLEN N, et al. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures[J]. Nat Med, 2021, 27(6):1034-1042. DOI PMID
[8]	GONZALEZ M C, ASHTON N J, GOMES B F, et al. Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with lewy bodies[J]. JAMA Neurol, 2022, 79(1):32-37.
[9]	BRICKMAN A M, MANLY J J, HONIG L S, et al. Plasma p-tau181,p-tau217,and other blood-based Alzheimer's disease biomarkers in a multi-ethnic,community study[J]. Alzheimers Dement, 2021, 17(8):1353-1364.
[10]	SUÁREZ-CALVET M, KARIKARI T K, ASHTON N J, et al. Novel tau biomarkers phosphorylated at T181,T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected[J]. EMBO Mol Med, 2020, 12(12):e12921.
[11]	MONTE S M, GHANBARI K, FREY W H, et al. Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid[J]. J Clin Invest, 1997, 100(12):3093-3104. PMID
[12]	金贺, 王蓉. 阿尔茨海默病相关神经丝蛋白(AD7c-NTP)的研究现状概述[J]. 老年医学与保健, 2019, 25(3):411-414.
[13]	GHANBARI H, GHANBARI K, BEHESHTI I, et al. Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker[J]. J Clin Lab Anal, 1998, 12(5):285-288. PMID
[14]	GHANBARI K, GHANBARI H A. A sandwich enzyme immunoassay for measuring AD7C-NTP as an Alzheimer's disease marker:AD7C test[J]. J Clin Lab Anal, 1998, 12(4):223-226.
[15]	XU M R, DAI R F, WEI Q Q, et al. Urinary AD7c-NTP evaluates cognition impairment and differentially diagnoses AD and MCI[J]. Am J Alzheimers Dis Other Demen, 2022,37:15333175221115247.
[16]	DE LA MONTE S M, WANDS J R. The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer's disease[J]. J Alzheimers Dis, 2001, 3(3):345-353. PMID
[17]	KU B D, KIM H, KIM Y K, et al. Comparison of urinary Alzheimer-associated neural thread protein(AD7c-NTP)levels between patients with amnestic and nonamnestic mild cognitive impairment[J]. Am J Alzheimers Dis Other Demen, 2020,35:1533317519880369.
[18]	ZHANG J, ZHANG C H, LI R J, et al. Accuracy of urinary AD7c-NTP for diagnosing Alzheimer's disease:a systematic review and meta-analysis[J]. J Alzheimers Dis, 2014, 40(1):153-159.
[19]	梁春华, 肖小华, 胡火有. 尿液AD7c-NTP与阿尔茨海默病[J]. 罕少疾病杂志, 2021, 28(4):109-112.
[20]	朱文波, 许秦风, 李晶晶, 等. 阿尔茨海默病的实验室检测与分子影像学检查的研究进展[J]. 中华检验医学杂志, 2020, 43(3):328-335.
[21]	刘彬, 计畅, 朱杨帆, 等. AD7c-NTP在临床科室中检测的意义[J]. 中国老年保健医学, 2017, 15(6):8-9.
[22]	郑戈, 毕兵, 朱晶, 等. 自贡地区健康体检中老年人群阿尔茨海默病患病调查及AD7C-NTP的相关性分析[J]. 中华养生保健, 2023, 41(20):90-93.
[23]	KAHLE P J, JAKOWEC M, TEIPEL S J, et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF[J]. Neurology, 2000, 54(7):1498-1504. PMID
[24]	MA L, WANG R, HAN Y, et al. Development of a novel urine Alzheimer-associated neuronal thread protein ELISA kit and its potential use in the diagnosis of Alzheimer's disease[J]. J Clin Lab Anal, 2016, 30(4):308-314. DOI PMID
[25]	WANG C, CUI Y, YANG J, et al. Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer's disease in patients with the apolipoprotein E ϵ4 genotype[J]. Biomarkers, 2015, 20(1):84-88. DOI PMID
[26]	WU M, LI Y, JI C, et al. Cloning and identification of a novel human gene PDLIM5,a homolog of AD-associated neuronal thread protein(AD7c-NTP)[J]. DNA Seq, 2004, 15(2):144-147.
[27]	KRIEGS J O, SCHMITZ J, MAKALOWSKI W, et al. Does the AD7c-NTP locus encode a protein?[J]. Biochim Biophys Acta, 2005, 1727(1):1-4. PMID
[28]	BAI B, WANG X, LI Y, et al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression[J]. Neuron, 2020, 105(6):975-991. DOI PMID
[29]	WANG Y, SUN Y, WANG Y, et al. Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease:findings based on urine proteomics and machine learning[J]. Alzheimers Res Ther, 2023, 15(1):191.
[30]	WATANABE Y, HIRAO Y, KASUGA K, et al. Molecular network analysis of the urinary proteome of Alzheimer's disease patients[J]. Dement Geriatr Cogn Dis Extra, 2019, 9(1):53-65. DOI PMID
[31]	陈德柱, 陶月, 蔡敏琪, 等. 临床血清磷酸化Tau蛋白检测结果回顾及试剂盒分析[J]. 东南大学学报(医学版), 2024, 43(2):256-262.

组别	例数	阳性例数/例	阳性率/ %
AD组	501	19	3.79
痴呆组	180	5	2.78
认知障碍组	298	6	2.01
帕金森病组	918	21	2.29
肌萎缩侧索硬化组	29	1	3.45
精神分裂症组	1 831	43	2.35
抑郁障碍组	1 414	27	1.91*
双相情感障碍组	707	17	2.40
脑梗死组	1 215	44	3.62
脑缺血组	644	13	2.02
头昏/头痛/晕厥/眩晕组	372	3	0.81*
器质性精神障碍组	287	5	1.74
心境障碍组	81	1	1.23
精神活性物质所致精神障碍组	174	2	1.15
癫痫组	152	2	1.32
脑炎组	85	2	2.35
周围神经病变组	87	4	4.60
脑出血组	77	5	6.49
多系统萎缩组	69	4	5.80
颅内占位性病变组	67	1	1.49
精神发育迟滞伴精神障碍组	27	2	7.41
药物中毒组	29	1	3.45
焦虑症组	35	1	2.86
强迫性神经症组	15	1	6.67
睡眠障碍组	34	3	8.82
脑外伤组	31	2	6.45
震颤组	32	2	6.25
分离性障碍/转换性障碍组	23	1	4.35
脑血管病所致精神障碍组	19	2	10.53
重症肌无力组	19	1	5.26
高血压组	17	1	5.88
耳聋组	14	1	7.14
脑动脉狭窄组	13	1	7.69
神经麻痹组	13	0	0.00
神经梅毒组	13	1	7.69
面肌痉挛组	10	2	20.00#Δ
其他组	676	12	1.78
合计	10 208	259	2.54

组别	例数	阳性例数/例	阳性率/ %
AD组	501	19	3.79
痴呆组	180	5	2.78
认知障碍组	298	6	2.01
帕金森病组	918	21	2.29
肌萎缩侧索硬化组	29	1	3.45
精神分裂症组	1 831	43	2.35
抑郁障碍组	1 414	27	1.91*
双相情感障碍组	707	17	2.40
脑梗死组	1 215	44	3.62
脑缺血组	644	13	2.02
头昏/头痛/晕厥/眩晕组	372	3	0.81*
器质性精神障碍组	287	5	1.74
心境障碍组	81	1	1.23
精神活性物质所致精神障碍组	174	2	1.15
癫痫组	152	2	1.32
脑炎组	85	2	2.35
周围神经病变组	87	4	4.60
脑出血组	77	5	6.49
多系统萎缩组	69	4	5.80
颅内占位性病变组	67	1	1.49
精神发育迟滞伴精神障碍组	27	2	7.41
药物中毒组	29	1	3.45
焦虑症组	35	1	2.86
强迫性神经症组	15	1	6.67
睡眠障碍组	34	3	8.82
脑外伤组	31	2	6.45
震颤组	32	2	6.25
分离性障碍/转换性障碍组	23	1	4.35
脑血管病所致精神障碍组	19	2	10.53
重症肌无力组	19	1	5.26
高血压组	17	1	5.88
耳聋组	14	1	7.14
脑动脉狭窄组	13	1	7.69
神经麻痹组	13	0	0.00
神经梅毒组	13	1	7.69
面肌痉挛组	10	2	20.00#Δ
其他组	676	12	1.78
合计	10 208	259	2.54

不同脑部疾病患者尿液AD7c-NTP阳性率分析

Positive rate analysis of urinary AD7c-NTP of patients with different brain diseases

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 31

相关文章 14

编辑推荐

Metrics

[1]	张蕴, 张洪阳, 徐建可. 幽门螺杆菌感染对脑梗死后血管性痴呆患者血清Hcy水平和认知功能的影响[J]. 检验医学, 2025, 40(5): 460-463.
[2]	侯玉丽, 王怡斐, 付静轩, 王培昌. 基于GEO数据库筛选阿尔茨海默病的关键基因及信号通路[J]. 检验医学, 2022, 37(7): 664-668.
[3]	娄小燕, 王涛, 高琼, 路伟, 李丹, 李振华, 林萍. 阿尔茨海默病患者环状RNA差异表达初步分析[J]. 检验医学, 2021, 36(11): 1114-1120.
[4]	李文正, 禹松林, 尹逸丛, 于佳磊, 王丹晨, 邹雨桐, 邱玲. AD患者血清核酸氧化损伤产物与抗氧化物质相关性分析[J]. 检验医学, 2021, 36(11): 1164-1168.
[5]	陈小童, 林勇. 阿尔茨海默病相关血液学标志物研究进展[J]. 检验医学, 2020, 35(4): 374-379.
[6]	李丹, 林萍, 金伟峰, 陈姝子, 李萍, 程训佳. 阿尔茨海默病患者糖、脂代谢与脂多糖的相关性[J]. 检验医学, 2020, 35(11): 1126-1129.
[7]	凌迎春, 周月琴, 段迪, 胡玲敏. 中枢神经特异蛋白对检测老年性痴呆的临床价值[J]. 检验医学, 2017, 32(11): 1021-1023.
[8]	丁彬彬, 邬建民, 介勇, 孙荣莲, 王晓燕. 阿尔茨海默病和血管性痴呆患者血清炎症因子和生化指标的检测及临床意义[J]. 检验医学, 2016, 31(5): 363-367.
[9]	陈同伟. 不同程度阿尔茨海默病患者血清可溶性Fas及其配体水平的变化[J]. 检验医学, 2015, 30(6): 564-566.
[10]	周会祥;朱建安;韩峰;谢福生;江永青. 人血浆β淀粉样蛋白42 ELISA的建立及其临床初步应用[J]. 检验医学, 2009, 24(08): 582-585.
[11]	杨志栋. 阿尔茨海默病患者脑脊液和血浆胰岛素水平检测的临床意义[J]. 检验医学, 2007, 22(02): 207-212.
[12]	王豪;瞿正万. 总抗氧化状态、高敏C反应蛋白联合血脂检测在早老性痴呆症诊断中的应用研究[J]. 检验医学, 2006, 21(05): 465-467.
[13]	陆元善. 载脂蛋白E多态性与老年性痴呆症的关系[J]. 检验医学, 1999, 14(6): 328-329.
[14]	孙蓓；齐玲俊. 老年痴呆症患者血清及脑脊液乳酸含量变化初探[J]. 检验医学, 1999, 14(2): 73-73.